LUMISIGHT™ and Lumicell™ Direct Visualization System (DVS) offer 84% diagnostic accuracy in detecting residual cancer, in real-time, that may have been otherwise missed during lumpectomy surgery, while sparing some from second surgeries   LUMISIGHT and Lumicell DVS previously received FDA Fast Track and Breakthrough Device designations, respectively    NEWTON, Mass., April 18, 2024—Lumicell, Inc., a … Continue reading Lumicell’s Cutting-Edge Imaging Platform Receives Historic FDA Approval to Illuminate Residual Breast Cancer